

Sheena K Aurora

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9598567/publications.pdf>

Version: 2024-02-01

14
papers

1,213
citations

759233

12
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

895
citing authors

#	ARTICLE	IF	CITATIONS
1	Periaqueductal Gray Matter Dysfunction in Migraine: Cause or the Burden of Illness?. <i>Headache</i> , 2001, 41, 629-637.	3.9	584
2	Gastric Stasis in Migraine: More Than Just a Paroxysmal Abnormality During a Migraine Attack . <i>CME. Headache</i> , 2006, 46, 57-63.	3.9	114
3	Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 996-1001.	1.9	105
4	MAP0004, Orally Inhaled DHE: A Randomized, Controlled Study in the Acute Treatment of Migraine. <i>Headache</i> , 2011, 51, 507-517.	3.9	84
5	Gastric stasis in migraineurs: Etiology, characteristics, and clinical and therapeutic implications. <i>Cephalalgia</i> , 2013, 33, 408-415.	3.9	51
6	Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example. <i>Journal of Pain</i> , 2015, 16, 164-175.	1.4	49
7	Gastric Stasis Occurs in Spontaneous, Visually Induced, and Interictal Migraine. <i>Headache</i> , 2007, 47, 1443-1446.	3.9	45
8	Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes. <i>Headache</i> , 2017, 57, 766-777.	3.9	40
9	What the Gut Can Teach Us About Migraine. <i>Current Pain and Headache Reports</i> , 2015, 19, 33.	2.9	35
10	The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. <i>Journal of Headache and Pain</i> , 2017, 18, 78.	6.0	34
11	A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection. <i>Headache</i> , 2021, 61, 576-589.	3.9	30
12	Sleep disturbances among pregnant women with history of migraines: A cross-sectional study. <i>Cephalalgia</i> , 2015, 35, 1092-1102.	3.9	15
13	STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD [®]) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. <i>Headache</i> , 2021, 61, 1214-1226.	3.9	14
14	The Upper Nasal Space—A Novel Delivery Route Ideal for Central Nervous System Drugs. <i>US Neurology</i> , 2020, 16, 25.	0.2	13